These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 25395843

  • 1. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S, Hamaya E, Sato M, Graham-Clarke P, Flynn JA, Burge R.
    Clin Interv Aging; 2014; 9():1879-93. PubMed ID: 25395843
    [Abstract] [Full Text] [Related]

  • 2. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY, Felsenberg D, Pavo I, Stepan J, Payer J, Resch H, Glüer CC, Mühlenbacher D, Quail D, Schmitt H, Nickelsen T.
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [Abstract] [Full Text] [Related]

  • 3. Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.
    Cranney A, Adachi JD.
    Drug Saf; 2005 Sep; 28(8):721-30. PubMed ID: 16048357
    [Abstract] [Full Text] [Related]

  • 4. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H, Ohashi Y, Taketani Y, Fukunaga M, Nakamura T, Itabashi A, Sarkar S, Harper K.
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D, Spencer CM.
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [Abstract] [Full Text] [Related]

  • 8. Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.
    Gorai I, Hattori S, Tanaka Y, Iwaoki Y.
    J Bone Miner Metab; 2012 May; 30(3):349-58. PubMed ID: 22130786
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    Endocr J; 2008 Mar; 55(1):41-8. PubMed ID: 18187874
    [Abstract] [Full Text] [Related]

  • 11. Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04.
    Uemura Y, Sone T, Tanaka S, Miyazaki T, Tsukiyama M, Taguchi A, Soen S, Mori S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) Research Group.
    Curr Med Res Opin; 2020 Nov; 36(11):1847-1859. PubMed ID: 32870712
    [Abstract] [Full Text] [Related]

  • 12. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [Abstract] [Full Text] [Related]

  • 13. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.
    Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA.
    Osteoporos Int; 2008 Aug; 19(8):1153-60. PubMed ID: 18256777
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC, Ying KY, To CH, Ho LY, Yu KL, Lee HK, Ma KM.
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.
    Osteoporos Int; 1999 May; 10(4):330-6. PubMed ID: 10692984
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW, Moffett AM, Ghosh A, Cox DA, Dowsett SA, Harper K.
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.